多模态影像显示靶向αvβ6/αvβ1整合素在胆汁性肝纤维化中的抗纤维化效果
该研究在胆管结扎大鼠中联合使用αvβ6整合素靶向PET(68Ga-DOTA-R01-MG)与I型胶原特异性MRI(CM-101),评估αvβ6/αvβ1抑制剂对靶点表达/结合及肝纤维化的影响。结果显示抑制剂降低肝脏PET摄取并减少胶原MRI测得的纤维化,组织学证实纤维化减轻。
要点
- 68Ga-DOTA-R01-MG PET可无创测量肝αvβ6表达及靶点结合。
- αvβ6/αvβ1抑制剂降低BDL大鼠肝PET摄取并减少胶原MRI纤维化信号。
- 分子MRI与PET联合方案可用于监测整合素抑制剂疗效。
核心结论
- 联合分子MRI与PET的单一影像方案可通过测量靶点表达/结合及治疗结果有效监测整合素抑制剂治疗,多模态分子影像可能有助于加速肝纤维化分子疗法药物开发。
研究设计与样本
- 在胆管结扎(BDL)大鼠中开展治疗研究,使用αvβ6/αvβ1小分子抑制剂;以68Ga-DOTA-R01-MG(αvβ6特异性PET探针)无创测量肝αvβ6表达及靶点结合,以CM-101(I型胶原MRI探针)定量纤维化;组织学验证。
关键影像表现/征象
- BDL大鼠术后17天肝脏68Ga-DOTA-R01-MG PET摄取较假手术大鼠高3倍。
- 影像前1小时给予高剂量αvβ6/αvβ1抑制剂预处理,BDL大鼠肝脏PET摄取显著降低31%(P=0.012)。
- 每日给药两周后,αvβ6 PET示抑制剂组肝αvβ6表达为0.27±0.07 %ID/mL,赋形剂组为0.40±0.09 %ID/mL(P=0.014)。
- 胶原MRI示抑制剂组肝弛豫率变化ΔR1为0.14±0.11,赋形剂组为0.36±0.06(P=0.0037)。
诊断标准与关键数值
- 组织学验证:抑制剂组胶原面积比例10.7±2.8%,赋形剂组22.5±6.1%(P<0.001)。
临床应用与阅片要点
- 联合αvβ6靶向PET与胶原特异性MRI可在活体同时评估靶点表达/结合与纤维化改变。
- 该方案可用于监测整合素抑制剂治疗反应,可能加速肝纤维化分子疗法药物开发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Development of molecular therapies for liver fibrosis is slowed by a lack of noninvasive methods addressing questions of target expression, target engagement, and treatment response. Integrin α v β 6 is a biomarker of liver fibrosis that is upregulated in livers of patients with primary sclerosing cholangitis. It activates latent TGF-β and plays a critical role in regulating extracellular matrix expression, especially collagen. In this study, our aim was to use combined α v β 6 integrin-targeted positron emission tomography (PET) and collagen-specific magnetic resonance imaging (MRI) to measure target expression/engagement and liver fibrosis reduction with a α v β 6 integrin inhibitor.
MATERIALS AND METHODS: We conducted a treatment study in bile duct-ligated (BDL) rats using a small molecule inhibitor to α v β 6 /α v β 1 . 68 Ga-DOTA-R01-MG, an α v β 6 -specific PET probe, was used to noninvasively measure α v β 6 expression and target engagement in the liver. CM-101, a type I collagen MRI probe, was used to quantify fibrosis.
RESULTS: 68 Ga-DOTA-R01-MG PET showed 3-fold higher liver uptake in BDL rats compared with sham rats at 17 days after surgery. Pretreatment with high dose α v β 6 /α v β 1 inhibitor 1 hour before imaging significantly decreased liver PET uptake in BDL rats (31%, P = 0.012). Two weeks of daily dosing with an α v β 6 /α v β 1 inhibitor attenuated α v β 6 expression in BDL rat liver as assessed by α v β 6 PET (0.27 ± 0.07 percent injected dose [%ID]/mL compared with 0.40 ± 0.09 %ID/mL in vehicle-treated group, P = 0.014) and reduced liver fibrosis as assessed by collagen MRI (liver relaxation rate change ΔR 1 = 0.14 ± 0.11 vs 0.36 ± 0.06, P = 0.0037). Imaging findings were confirmed by histology (collagen proportionate area 10.7 ± 2.8% vs 22.5 ± 6.1%, P < 0.001).
CONCLUSIONS: A single imaging protocol combining molecular MRI and PET can be used to effectively monitor integrin inhibitor treatment by measuring target expression/engagement and treatment outcomes. Multimodality molecular imaging may be valuable in accelerating drug development in molecular therapies for liver fibrosis.
引用
- Ning Y, Zhou IY, Schaub JR, et al. Multimodal Imaging Demonstrates Antifibrotic Effects of Targeting α v β 6 /α v β 1 Integrins in Biliary Fibrosis. Invest Radiol. 2026. PMID: 40306257. doi:10.1097/RLI.0000000000001202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。